Baricitinib (Olumiant▼): increased risk of diverticulitis, particularly in patients with risk factors

Cases of diverticulitis (DV) and GI perforation have been reported in patients taking baricitinib; most, but not all, cases occurred in patients on concomitant medicines linked to increased risk of DV, therefore baricitinib should be used with caution in these particular groups.

Source:

Medicines and Healthcare products Regulatory Agency